Drug eluting ocular implant
First Claim
Patent Images
1. A drug delivery ocular implant comprising:
- an elongate outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior lumen;
at least a first active drug positioned within said interior lumen,wherein said first active drug is present as one or more micro-tablets,wherein said micro-tablets have a density of about 0.7 g/cc to about 1.6 g/cc,wherein said outer shell comprises a first thickness; and
wherein said outer shell comprises one or more regions of drug release, wherein the one or more regions of drug release comprise one or more orifices,wherein at least one of the one or more orifices comprises a hydrogel plug in or adjacent to the orifice, andwherein the first active drug passes through the hydrogel plug as it elutes from the implant the hydrogel plug thereby at least in part defining an elution rate of the first active drug from the implant.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
156 Citations
20 Claims
-
1. A drug delivery ocular implant comprising:
-
an elongate outer shell having a proximal end, a distal end, said outer shell being shaped to define an interior lumen; at least a first active drug positioned within said interior lumen, wherein said first active drug is present as one or more micro-tablets, wherein said micro-tablets have a density of about 0.7 g/cc to about 1.6 g/cc, wherein said outer shell comprises a first thickness; and wherein said outer shell comprises one or more regions of drug release, wherein the one or more regions of drug release comprise one or more orifices, wherein at least one of the one or more orifices comprises a hydrogel plug in or adjacent to the orifice, and wherein the first active drug passes through the hydrogel plug as it elutes from the implant the hydrogel plug thereby at least in part defining an elution rate of the first active drug from the implant. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
-
Specification